Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025
Changes in Tumor Size Track Advanced RCC Outcomes, Analyses From CLEAR Show
Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event
Characterizing Patients With MDS Who Undergo Allo-HSCT
Venetoclax Shows Good Results Even in Short-Telomere Patients With CLL
Exploring Response to HMAs for MDS Across Various Patient Types
Pain, Fatigue With Bimekizumab for PsA Tied to Swollen Joints
BTKi Resistance Mechanisms, Solutions Probed at ASH
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
Identifying Patients With Low-Risk Breast Cancer for De-escalated Therapy
Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024
Studies Examine Real-World Pediatric AML Treatment and Outcomes
ICYMI: Highlights From SPD 2024
ICYMI: Highlights From ASH 2024
ICYMI: Highlights From WCLC 2024
ICYMI: Highlights From AMCP Nexus 2024
Research Supports Need for Diversity in Hemophilia Trials and Reducing Resource Strain
Top 5 Multiple Myeloma Content of 2024
ICYMI: Highlights From AUA 2024
ICYMI: Highlights From AAD 2024
ICYMI: Highlights From ASCO 2024
ICYMI: AHA 2024 Scientific Session Highlights
Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab
ICYMI: Highlights From AMCP Annual 2024
ICYMI: Highlights From CHEST 2024
The Role of Geriatric Assessment Tools in Enhancing Oncology Care: ASH 2024
ICYMI: Highlights From SLEEP 2024
Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL
Top 5 Conference Coverage of 2024